U.S. markets close in 3 hours 24 minutes

Sight Sciences, Inc. (SGHT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
23.24-1.39 (-5.63%)
As of 12:35PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close24.62
Open24.45
Bid23.02 x 1000
Ask23.15 x 2900
Day's Range23.04 - 24.63
52 Week Range22.82 - 42.57
Volume113,337
Avg. Volume431,868
Market Cap1.098B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-5.00
Earnings DateAug 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Sight Sciences, Inc.
    GKOS: What does Argus have to say about GKOS?GLAUKOS CORP has an Investment Rating of SELL; a target price of $41.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • GlobeNewswire

    Sight Sciences Files Lawsuit Against Ivantis for Patent Infringement

    Sight Sciences Seeks Injunction Related to Hydrus® Microstent’s InfringementMENLO PARK, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ: SGHT) today announced that it filed a lawsuit in the United States District Court in Delaware against Ivantis, Inc. for infringement of U.S. Patent Numbers 8,287,482, 9,370,443, 9,486,361, and 10,314,742. These patents describe and claim devices and methods for reducing intraocular pressure in the eye. Sight Sciences’ complaint seeks an

  • GlobeNewswire

    Sight Sciences to Participate in the Morgan Stanley Global Healthcare Conference

    MENLO PARK, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on developing and commercializing devices designed to address the underlying causes of the world's most prevalent eye diseases, today announced plans to participate in the upcoming virtual Morgan Stanley Global Healthcare Conference. Sight Sciences’ management is scheduled to present Thursday, September 9, 2021 at 9:30am ET. Interested parties may access a live

  • GlobeNewswire

    Sight Sciences, Pioneering the Development of the Standalone MIGS Market, Announces Publication of Favorable Two-Year Outcomes of Standalone Use of the OMNI® Surgical System in Mild to Moderate Open-Angle Glaucoma

    Real-world data published in Clinical Ophthalmology show the safety, efficacy, and durability of effect of OMNI for use in a standalone procedure to reduce intraocular pressure and medication burdenMENLO PARK, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on developing and commercializing devices designed to address the underlying causes of the world's most prevalent eye diseases, today announced publication in Clinic